Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Atyr PHARMA in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings per share of ($0.87) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Atyr PHARMA's current full-year earnings is ($0.91) per share.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.01).
Other equities research analysts have also recently issued reports about the company. HC Wainwright restated a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Wells Fargo & Company assumed coverage on shares of Atyr PHARMA in a research report on Friday, October 4th. They issued an "overweight" rating and a $17.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Atyr PHARMA presently has an average rating of "Buy" and an average target price of $19.25.
Read Our Latest Research Report on Atyr PHARMA
Atyr PHARMA Price Performance
Shares of ATYR traded down $0.12 during mid-day trading on Wednesday, hitting $3.51. The stock had a trading volume of 637,277 shares, compared to its average volume of 966,076. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The company has a market capitalization of $294.63 million, a price-to-earnings ratio of -3.73 and a beta of 1.08. Atyr PHARMA has a 52 week low of $1.42 and a 52 week high of $4.22. The stock's fifty day moving average price is $3.40.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Atyr PHARMA stock. JPMorgan Chase & Co. boosted its stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) by 52.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,440 shares of the company's stock after purchasing an additional 10,754 shares during the quarter. JPMorgan Chase & Co.'s holdings in Atyr PHARMA were worth $55,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 61.72% of the company's stock.
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Further Reading
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
